Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$298 Mln
P/E Ratio
--
P/B Ratio
1.15
Industry P/E
--
Debt to Equity
0.32
ROE
-0.79 %
ROCE
-61.15 %
Div. Yield
0 %
Book Value
5.1
EPS
-4.46
CFO
$-395.60 Mln
EBITDA
$-754.26 Mln
Net Profit
$-684.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Regenxbio Inc (RGNX)
| -13.71 | -20.22 | -9.50 | -57.49 | -40.04 | -28.73 | -- |
|
BSE Sensex*
| 1.74 | 3.51 | 4.97 | 8.92 | 11.19 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Regenxbio Inc (RGNX)
| -56.64 | -20.86 | -30.64 | -27.91 | 10.72 | -2.34 | 26.01 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary... adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Address: 9804 Medical Center Drive, Rockville, MD, United States, 20850 Read more
President, CEO & Director
Mr. Kenneth T. Mills
President, CEO & Director
Mr. Curran M. Simpson M.S.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Regenxbio Inc (RGNX) stood at $ 466 Mln as on 31-Dec-24
The share price of Regenxbio Inc (RGNX) is $6.67 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Regenxbio Inc (RGNX) has given a return of -40.04% in the last 3 years.
Regenxbio Inc (RGNX) has a market capitalisation of $ 298 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Regenxbio Inc (RGNX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Regenxbio Inc (RGNX) and enter the required number of quantities and click on buy to purchase the shares of Regenxbio Inc (RGNX).
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Address: 9804 Medical Center Drive, Rockville, MD, United States, 20850
The CEO & director of Mr. Kenneth T. Mills. is Regenxbio Inc (RGNX), and CFO & Sr. VP is Mr. Curran M. Simpson M.S..
There is no promoter pledging in Regenxbio Inc (RGNX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Regenxbio Inc (RGNX) | Ratios |
|---|---|
|
Return on equity(%)
|
-79.49
|
|
Operating margin(%)
|
-257.35
|
|
Net Margin(%)
|
-272.54
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Regenxbio Inc (RGNX) was $0 Mln.
$0.73
(
